Baldus S E, Palmen C, Thiele J
Institute of Pathology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Histol Histopathol. 2007 Aug;22(8):889-93. doi: 10.14670/HH-22.889.
MUC1 (also called: epithelial membrane antigen, EMA) represents a mucin molecule strongly expressed in various epithelia and epithelial neoplasms. Its expression correlates with clinical and pathological factors as well as prognosis in some tumor types. Additionally, MUC1 was detected in normal haematopoietic cell lines and neoplasms, especially subgroups of human lymphomas including plasma cell myeloma. Therefore, the expression of MUC1 in trephine biopsies exhibiting infiltrates of plasma cell myeloma were investigated immunohistochemically. An immunoreactivity of two monoclonal antibodies (EMA and HMFG-2) was observed in about 50% of the cases. In cases exhibiting a so-called packed marrow, EMA immunoreactivity was reduced. However, MUC1 positivity did not correlate with the cytologic grade of differentiation, the fibre content of the marrow, or survival probability of the patients. However, its strong expression in a certain percentage of cases of plasma cell myeloma may be of therapeutic impact, since new therapeutic strategies include the enrichment of MUC1-specific T cells or MUC1 vaccination.
MUC1(也称为:上皮膜抗原,EMA)是一种在各种上皮组织和上皮性肿瘤中强烈表达的粘蛋白分子。其表达与某些肿瘤类型的临床和病理因素以及预后相关。此外,在正常造血细胞系和肿瘤中检测到MUC1,特别是在包括浆细胞骨髓瘤在内的人类淋巴瘤亚组中。因此,采用免疫组织化学方法研究了MUC1在显示浆细胞骨髓瘤浸润的骨髓活检组织中的表达情况。在约50%的病例中观察到两种单克隆抗体(EMA和HMFG-2)的免疫反应性。在表现为所谓“密集骨髓”的病例中,EMA免疫反应性降低。然而,MUC1阳性与细胞分化程度、骨髓纤维含量或患者生存概率无关。然而,其在一定比例的浆细胞骨髓瘤病例中的强表达可能具有治疗意义,因为新的治疗策略包括富集MUC1特异性T细胞或进行MUC1疫苗接种。